The UK is the first country in the world to have approved the Pfizer BioNTech coronavirus vaccine for use and has announced that it will launch early next week.
“The government today adopted the recommendation of the Independent Medicines and Health Products Regulatory Authority (MHRA) Pfizer-BioNTech’s Covid-19 vaccine approved for use“The British government was quoted by Reuters.” The vaccine will be available across the UK from next week, “added the UK government.
The UK vaccines committee will decide which priority groups get the sting first, such as nursing home residents, health and care workers, the elderly and people at extreme clinical risk, the report added.
Health Secretary Matt Hancock said the program would begin early next week. Hospitals, he said, are already ready to receive it. “It’s very good news,” said Hancock.
What about the effectiveness of the Pfizer BioNTech vaccine?
Pfizer said the UK’s emergency approval was a historic moment in the fight against the coronavirus.
Both Pfizer-BioNTech and the US biotech company Moderna have reported preliminary results from more than 90% effectiveness – an unexpectedly high rate – in studies with their vaccines.
“This approval is a goal we have been working towards since we first stated that science will win and we applaud the MHRA for its ability to carry out a careful assessment and take timely action to protect the people of the UK “said CEO Albert Bourla told Reuters.
“As we await further approvals and approvals, our focus is on delivering a safe vaccine safely around the world with the same urgency.”
Together with Moderna, Pfizer-BioNTech applied for EU emergency approval for its Covid-19 vaccines on Tuesday. Pfizer and its German development partner BioNTech said their vaccine could be launched in the European Union as early as this month. In response to the request, the European Medicines Agency (EMA) announced that it had received formal requests from both vaccine manufacturers to receive the green light for their experimental bursts.
“If the data submitted are robust enough to infer the quality, safety and effectiveness of the vaccine,” the Amsterdam-based agency said it could finalize its assessment of the BioNTech / Pfizer shot at an extraordinary meeting in December at the latest. .
ALSO READ | Covid-19 vaccine: Mera number Kab Aayega?
Comments
Post a Comment